Readers Share Personal Insights About Deadly Denials and Pregnancy Centers
Letters to the editor is a periodical article. We welcome all comments and will publish a selection. We edit for…
Health
Discover the Latest Health, Medicine, Nutrition, and Fitness Tips for Women, Men, and Children
Childhood vaccination rate increases slightly, but millions remain unprotected
WHO and UNICEF annual estimates of national immunization coverage reveal 90 percent of infants worldwide received at least one dose…
The biotechnology recovery is not a farce. These 3 stocks could lead the next bullish leg
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
Lawmakers seek to make laws protecting abortion less dependent on who is governor
When Gov. Gavin Newsom, using his executive power, refused to extradite a doctor accused of prescribing and mailing abortion pills…
Cramer Says This Stock Is Significantly Undervalued And Sees 35% Upside
Every weekday, CNBC's Investment Club with Jim Cramer hosts a livestream “morning meeting” at 10:20 a.m. ET. Here's a recap…
Restoring dignity: Senegalese surgeon and Burundian foundation win reproductive health awards
The UN sexual and reproductive health agency, UNFPA, announced on Wednesday that the individual award will go to Professor Serigne…
Employers Are Not Expanding Coverage of GLP-1 Anti-Obesity Drugs: Survey
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
They harvest the country's food, but a new rule could strip them of health insurance
Seasonal work. Inconsistent schedules. Frequent movements. Cash payments and informal jobs. For farmworkers who rely on Medicaid, these common employment…
World must accelerate Ebola response in DR Congo: UN aid chief
Fletcher warned that while Ituri province remains the center of the outbreak, the virus is spreading to other provinces due…
AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…